Search

Displaying results 6161 - 6170 of 10000 in total
  1. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

  2. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.

  3. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. … It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]

  4. Drug

    2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid

    go.drugbank.com/drugs/DB19221
    Investigational

    2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid is under investigation in clinical trial NCT03774394 (Impact of Chronic Kidney Disease on Clopidogrel Effects in

  5. Drug

    LX201

    go.drugbank.com/drugs/DB04943
    Investigational

    LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. … The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc.

  6. Drug

    Volinanserin

    go.drugbank.com/drugs/DB16351
    Investigational

    Volinanserin is under investigation in clinical trial NCT00464243 (Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study).

  7. Drug

    PV903

    go.drugbank.com/drugs/DB05163
    Experimental

    PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.

  8. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    ’s and Schizophrenia, an unmet medical need. … SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

  9. Drug

    BZL101

    go.drugbank.com/drugs/DB05051
    Investigational

    BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.

  10. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

    Categories: GABA-A Receptor Agonists